Global Oncology

CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.

The CHMP has recommended datopotamab deruxtecan for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.

Izalontamab brengitecan was approved in China for recurrent/metastatic NPC following disease progression on chemotherapy and PD-1/PD-L1 inhibition.

The European Commission approved perioperative pembrolizumab plus enfortumab vedotin for patients with cisplatin-ineligible resectable MIBC.

The European Commission approved first-line sacituzumab govitecan as monotherapy for unresectable/metastatic TNBC not eligible for PD-(L)1 inhibition.

China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.

LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma.

The EU has approved the use of subcutaneous isatuximab delivered via OBI across all existing indications for IV isatuximab for multiple myeloma.

Ultra-low-dose nivolumab plus oral metronomic chemotherapy cut the risk of death by 43% versus paclitaxel-carboplatin in first-line platinum-sensitive recurrent or metastatic HNSCC.

The CHMP granted a positive opinion to perioperative pembrolizumab/enfortumab vedotin as well as pembrolizumab and berahyaluronidase alfa in MIBC.

CHMP recommended trastuzumab deruxtecan for HER2-positive (IHC 3+) metastatic solid tumors, marking the first tumor-agnostic ADC opinion in the EU.

CHMP recommends camizestrant plus CDK4/6 inhibitor for ESR1-mutated HR+/HER2– advanced breast cancer, based on SERENA-6 phase 3 trial data.

Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.

Data from a real-world analysis demonstrated the efficacy and safety of CAR T-cell therapy in primary mediastinal B-cell lymphoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Tafasitamab in combination with rituximab and lenalidomide has been approved for relapsed or refractory follicular lymphoma in Australia.

Tovorafenib has received conditional marketing authorization in Europe for patients at least 6 months of age with BRAF-positive relapsed/refractory pLGG.

China’s NMPA approved belantamab mafodotin plus Vd for the treatment of relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Zevor-cel produced durable responses in patients with relapsed/refractory multiple myeloma following at least 3 prior lines of therapy.

A BLA has been accepted in China seeking the approval of second-line trastuzumab pamirtecan for unresectable or metastatic HER2-positive breast cancer.

Catch up on insights into the global development of breast cancer therapies that are making waves around the world.

Read our recap of top phase 1 and 2 breast cancer data announcements and highlights that may influence further clinical research and developments.

Pembrolizumab plus paclitaxel, with or without bevacizumab, is approved in the EU for pretreated platinum-resistant ovarian cancer with PD-L1 expression.